Endowment Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$703K Sell
765
-22
-3% -$22.3K 0.31% 64
2025
Q4
$846K Buy
787
+324
+70% +$310K 0.39% 55
2025
Q3
$354K Sell
463
-5
-1% -$3.72K 0.16% 102
2025
Q2
$365K Sell
468
-16
-3% -$12.4K 0.19% 92
2025
Q1
$400K Buy
484
+22
+5% +$18.3K 0.26% 77
2024
Q4
$356K Sell
462
-16
-3% -$13.2K 0.24% 85
2024
Q3
$424K Sell
478
-6
-1% -$5.39K 0.28% 74
2024
Q2
$438K Sell
484
-14
-3% -$11.2K 0.32% 70
2024
Q1
$388K Sell
498
-24
-5% -$17.1K 0.29% 74
2023
Q4
$304K Sell
522
-30
-5% -$17.5K 0.25% 90
2023
Q3
$296K Sell
552
-155
-22% -$79.9K 0.27% 93
2023
Q2
$331K Buy
707
+39
+6% +$16.4K 0.3% 86
2023
Q1
$229K Sell
668
-13
-2% -$4.38K 0.23% 112
2022
Q4
$249K Buy
681
+7
+1% +$2.48K 0.27% 101
2022
Q3
$218K Buy
674
+45
+7% +$14.3K 0.26% 98
2022
Q2
$204K Buy
+629
New +$189K 0.25% 101

Other funds holding LLY

Endowment Wealth Management's LLY Position: Q1 2026 in Review

Endowment Wealth Management reduced its Eli Lilly (LLY) stake by 2.8% in Q1 2026, selling an estimated $22.3K and leaving 765 shares worth $703K. The position accounts for 0.31% of the portfolio, ranked #64.

Endowment Wealth Management first reported a position in LLY in Q2 2022 and has held it in 16 quarters since. The position peaked at $846K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Endowment Wealth Management held 765 shares of Eli Lilly worth $703K as of Q1 2026.
  • Endowment Wealth Management sold 22 Eli Lilly shares in Q1 2026, an estimated $22.3K.
  • Eli Lilly made up 0.31% of Endowment Wealth Management's portfolio in Q1 2026, its #64 holding.
  • Endowment Wealth Management first reported a position in Eli Lilly in Q2 2022 and has held it in 16 quarters since.
  • Endowment Wealth Management's Eli Lilly position peaked at $846K in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Endowment Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.